Officer sold
~$529KReported value · 5,691 sh @ $92.95
Stock since the trade −2.0% · S&P 500 +1.4% · to Oct 5
Zimmer Biomet's Grp Pres-Global Business sold $529K of Zimmer Biomet shares. Nobody planned it ahead of time.
Loading…
ZBH · NYSE · Health Care Equipment
Health Care Equipment company based in Warsaw, Indiana.
In the last 90 days, no insider of Zimmer Biomet reported an open-market purchase and 2 open-market sales worth about $824K. Members of Congress disclosed 1 trade in its stock. The latest 13F reports cover the quarter ending Jun 30, 2026. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$91.57
Last 12 months
−9.1%
Market value
$17.5B
S&P 500 +15.8% over the same dates. Prices adjusted for splits and dividends.
Bets against the stock: 8.58M shares sold short (4.5% of shares outstanding), −2.4% vs the previous count, 4.4 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$2.18B
+4.8% vs the same quarter a year earlier
Free cash flow, last 12 months
$1.52B
This quarter $394M, a year earlier $328M
Net debt
$7.07B
Debt $7.48B, cash $410M, at Jun 30, 2026
Net income, last 12 months
$807M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 5, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
2 sales
$824K sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$8.23B
+7.2% vs the year before
Net income, fiscal 2025
$705M
As reported in the annual filing
Shares outstanding
191M
As of Jul 30, 2026
In fiscal 2025 the company spent $487M buying back its own shares and $190M on dividends. Cash actually paid, from its cash-flow statement.
Stock since the trade −2.0% · S&P 500 +1.4% · to Oct 5
Zimmer Biomet's Grp Pres-Global Business sold $529K of Zimmer Biomet shares. Nobody planned it ahead of time.
Officer sold ~$295K of Zimmer Biomet
Automatic saleOfficer plans to sell ~$295K of Zimmer Biomet
Planned, from payFrom a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
0 certified in FY2026 Q3, vs 1 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Short sale volume: 48.2% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 59.4%. FINRA daily files, to Oct 5, 2026.
Fails to deliver: 16K shares (about $1.65M) were not delivered on time for settlement on Aug 24, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Last 12 months, adjusted daily closes
Adjusted close went from $98.83 on Oct 6, 2025 to $91.57 on Oct 5, 2026 (-7.3%). Disclosed activity in the last 12 months: 0 insider purchases, 6 insider sales (2 under pre-arranged plans), 1 Congress purchase, 0 Congress sales, 1 fund report of opening or adding and 0 fund reports of trimming or selling out (13F, quarter-end snapshots).
Dodge & Cox
Schedule 13G: passive · filed Aug 13, 2026 · 24.1M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 14.8M shares
Capital International Investors
Schedule 13G: passive · filed Aug 12, 2026 · 12.4M shares
HARRIS ASSOCIATES L P
Schedule 13G: passive · filed Feb 17, 2026 · 12.3M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
16 approvals or clearances and 35 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Top officer leaving
“(the “Company”) of his intention to resign from the position of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain of the Company, effective as of April 28, 2026, to pursue a new professional opportunity.”
1 insider sold ~$251K in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.